Amgen cutbacks don’t let up




 
Thousand Oaks-based biotech giant Amgen has announced another round of layoffs. This time, however, they won’t affect its local headquarters.
The reorganization will result in about 300 jobs lost from its Onyx Pharmaceuticals facilities in San Francisco.
Amgen purchased Onyx Pharmaceuticals, which produces cancer drugs, for $9.7 billion in October 2013.
In a companywide March 9 memo, Amgen chair/CEO Bob Bradway said Amgen will consolidate its commercial and development oncology work...

Thank you for supporting your local Acorn! You need to be a digital subscriber to view the rest of this content. Please Login or Subscribe Now!